Showing results (141-150 of 398) with videos related to
Sort By:
Pageof 40
European Journal of Cancer (Oxford, England : 1990)|August 19, 2022
Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failureShinkyo Yoon, Sang Joon Shin, Ho Cheol Kim, et al.Cancer Chemotherapy and Pharmacology|May 25, 2011
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trialSe Hyun Kim, Sang Joon Shin, Sun Young Kim, et al.Oncotarget|January 4, 2018
Correlation between MEK signature and Ras gene alteration in advanced gastric cancerSoomin Ahn, Roz Brant, Alan Sharpe, et al.Urologic Oncology|April 5, 2023
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysisJae-Lyun Lee, Chirag Desai, Se Hoon Park, et al.Cancer Chemotherapy and Pharmacology|November 30, 2012
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapySun Jin Sym, Junshik Hong, Jinny Park, et al.Cancer Research and Treatment|February 25, 2025
Epidermal Growth Factor Receptor Aberrations Identified by Next-generation Sequencing in Patients with Metastatic CancersMinkyue Shin, Dae-Ho Choi, Jaeyun Jung, et al.Cancer|January 11, 2007
Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancerSe Hoon Park, Soo Jin Choi, Sun Young Kyung, et al.Oncology|July 16, 2005
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancerEun Kyung Cho, Woon Ki Lee, Seok-Ah Im, et al.Journal of Cancer|December 17, 2019
Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-MatchingMinyong Kang, Heejin Yoo, Kyunga Kim, et al.Cancer Research and Treatment|February 15, 2016
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched AnalysisSe-Il Go, Young Saing Kim, In Gyu Hwang, et al.Pageof 40